Recent News

• 04.16.2025 - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
• 04.16.2025 - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.11.2025 - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
• 03.11.2025 - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Recent Filings

• 04.11.2025 - S-3 Registration statement under Securities Act of 1933
• 04.11.2025 - POS AM Post-Effective amendments for registration statement
• 04.11.2025 - PRE 14A Other preliminary proxy statements
• 04.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - 8-K Current report
• 03.11.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.10.2025 - EX-99.1 EX-99.1